On Monday, Following U.S. Stocks were among the “Top Losers”: Neuralstem, Inc. (NYSEMKT:CUR), Ampio Pharmaceuticals Inc (NYSEMKT:AMPE), BreitBurn Energy Partners L.P. (NASDAQ:BBEP), Warren Resources, Inc. (NASDAQ:WRES)
Neuralstem, Inc. (NYSEMKT:CUR), with shares declined -7.42%, closed at $2.37.
Ampio Pharmaceuticals Inc (NYSEMKT:AMPE), with shares dropped -6.77%, settled at $7.44.
BreitBurn Energy Partners L.P. (NASDAQ:BBEP), with shares dipped -6.61%, and closed at $5.79.
Warren Resources, Inc. (NASDAQ:WRES), plummeted -6.12%, and closed at $0.990.
Latest NEWS regarding these Stocks are depicted underneath:
Neuralstem, Inc. (NYSEMKT:CUR)
Neuralstem, Inc. (CUR), stated its financial results for the fourth quarter and year ended December 31, 2014.
2014 Clinical Program and Business Highlights:
Neurogenic Small Molecule Platform Clinical Development
NSI-189 Phase II clinical trial for the treatment of MDD is predictable to commence in the second quarter of 2015. Maurizio Fava, M.D., Slater Family Professor of Psychiatry at Harvard Medical School, Massachusetts General Hospital is the principal investigator for the 150-patient, multi-site clinical trial.
Top-line data for the NSI-189 Phase Ib MDD trial. The data was presented at the American Society of Clinical Psychopharmacology (ASCP) and the International College of Neuropyschopharmacology (CiNP) annual meetings. The randomized, placebo-controlled, dose-escalation study showed clinically meaningful and statistically noteworthy results in depressive and cognitive measurements at the end of the 28-day dosing period. Moreover, therapeutic benefits were sustained over the 8-week follow-up period signaling possible hippocampal neurogenesis.
NSI-189 MDD biomarker data. In November 2014, researchers presented Phase Ib blood-based biomarker data and analysis for MDD in a poster at the CNS Summit, which identified a rapid and persistently efficacious response.
Expansion of NSI-189 development program to a second indication for the treatment of cognitive deficit in schizophrenia. Cognitive deficit in schizophrenia is a prominent characteristic of the disorder that is correlated with the occurrence of hippocampal atrophy in this patient population. Commencement of the Corporation’s NSI-189 cognitive deficit in schizophrenia Phase Ib trial is predictable in 2015.
2014 Business Highlights:
Board of Directors: Neuralstem designated two independent directors to its Board of Directors in 2014, Catherine Angell Sohn, Pharm.D. and Sandford Drexel Smith. Dr. Sohn is the former Senior Vice President of Business Development and Planned Alliance, GSK Consumer Healthcare, at GlaxoSmithKline. Mr. Smith is the former Executive Vice President of Genzyme Corporation.
Financial: In January 2014, Neuralstem closed a $20 million registered direct offering with proceeds intended to fund its ongoing clinical trials and corporate operations.
Neuralstem’s patented technology enables the production of multiple types of central nervous system (CNS) stem cells in commercial quantities for the potential treatment of certain CNS diseases and conditions.
Breitburn Energy Partners L.P. (NASDAQ:BBEP)
Breitburn Energy Partners L.P. (NASDAQ:BBEP), declared that Breitburn’s 2014 Individual Tax Reporting Packages, counting Plan K-1, have been mailed and are also accessible to download from the corporation’s website at www.taxpackagesupport.com/breitburn.
Unitholders who elected for electronic (paperless) delivery of their Individual Tax Reporting Packages must log-on to the website to download the tax packages. Tax Reporting Packages are accessible for: Breitburn Energy Partners LP Ordinary Units, QR Energy, LP Ordinary Units, and Breitburn Energy Partners LP Series A Cumulative Redeemable Perpetual Preferred Units (BBEPP).
BreitBurn Energy Partners LP, an independent oil and gas partnership, attains, exploits, and develops oil, natural gas liquids (NGLs), and natural gas properties in the United States. Breitburn’s producing and non-producing crude oil and natural gas reserves are located in the following seven areas: Ark-La-Tex, Michigan/Indiana/Kentucky, the Permian Basin, the Mid-Continent, the Rockies, Florida, and California.
Warren Resources Inc. (NASDAQ:WRES)
Warren Resources Inc. (WRES), stated its fourth quarter and full-year 2014 financial and operating results.
In declaring the results, Lance Peterson, Interim Chief Executive Officer, commented, “2014 was a transformational year for Warren, with strong growth in reserves, production, proceeds and cash flows and the successful execution of the attainment and integration of the Marcellus assets. While there has been noteworthy volatility in commodity prices and the capital markets recently, Warren has an asset base well positioned to successfully navigate the current market environment. As operator of all three of our main assets, the Corporation was able to right-size its development activity to reduce capital spending and focus on identifying additional capital and operating cost reductions going forward. Through our control of high influence wells in our Marcellus business unit and ownership of our drilling rig in the Wilmington field in California, Warren can respond quickly to changes in the commodity market. In addition, the Corporation will continue to identify opportunities to further raise its liquidity position. In keeping with Warren’s planned aim of becoming a more growth oriented corporation, we remain focused on identifying areas for future growth and ways to add value for shareholders and expect the current market environment will offer noteworthy opportunities for accretive investments. I am confident in our ability to execute on these aims and am optimistic about Warren’s potential going forward.”
Warren’s oil and gas proceeds raised 25% to $39.8 million in the fourth quarter of 2014, contrast to $31.7 million in the fourth quarter of 2013. This primarily resulted from the raise in production volumes in the fourth quarter of 2014 contrast to the fourth quarter of 2013.
The Corporation stated a net gain on derivative financial instruments of $6.4 million during the three months ended December 31, 2014, comprised of $3.2 million realized cash gains on commodity derivatives and $3.2 million of unrealized, non-cash gains on commodity derivatives.
At December 31, 2014, Warren had about $1.7 million in cash and cash equivalents, with $134.7 million outstanding under its $225 million borrowing base and accessible borrowing capacity of $90.3 million, for total accessible liquidity of $92.0 million. Warren’s next borrowing base redetermination will be in April.
Warren Resources, Inc. is an independent energy corporation engaged in the attainment, exploration, development and production of domestic oil and natural gas reserves. Warren’s activities are primarily focused on oil in the Wilmington field in the Los Angeles Basin in California, and natural gas in the Marcellus Shale in Pennsylvania and Washakie Basin in Wyoming.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should might occur.
